로딩 중…
지수 로딩 중…
Celemics, Inc.
331920· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩13,000-8.32%
2026-06-19
Price Chart
Celemics, Inc.+316.67%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 127.36B KRW |
| Revenue | 4.97B KRW |
| Net Income | 2.62B KRW |
| Total Assets | 22.87B KRW |
| Net Assets | 17.50B KRW |
| Employees | 42 |
| Value | |
| P/E | 48.54x |
| P/B | 7.28x |
| P/S | 25.63x |
| FCF Yield | -2.95% |
| Profitability | |
| ROE | 14.99% |
| ROA | 11.47% |
| Op. Margin | -28.89% |
| Revenue Growth | -46.39% |
| Financial Health | |
| Debt Ratio | 130.65% |
| Total Debt | 3.47B KRW |
| FCF | -3.76B KRW |
| Cash | 6.66B KRW |
| Current Ratio | 6.65x |
| Performance | |
| 1Y Return | 316.67% |
| 1M Return | -7.80% |
| From 52W High | -34.48% |
| 1Y MDD | -28.57% |
| Trading | |
| Volume | 93,049 shares |
| Foreign Own. | 1.06% |
| Per Share | |
| EPS | -960 KRW |
| BPS | 2,144 KRW |
Company Info
CeleMix was established in 2010 to manufacture and analyze basic pharmaceutical substances and biological preparations, and was specially listed on the KOSDAQ market in 2020 as a technology growth company. This venture company specializes as an NGS-based gene analysis technology platform, producing and selling MSSIC-based Target Capture Kits and BTSeq sequencing solutions. It develops DNA-related cloning technologies through technology convergence across biotechnology, nanotechnology, and information technology, supplying essential materials to various sectors. CeleMix is headquartered in Geumcheon-gu, Seoul.